Weight Loss Peptide Stack: The Multi-Receptor Approach
Semaglutide
GLP-1 receptor agonist — appetite suppression, delayed gastric emptying, central satiety signalling
Cagrilintide
Long-acting amylin analogue — complementary satiety signalling, delayed gastric emptying via distinct receptor pathway
The pharmaceutical industry is actively pursuing multi-receptor approaches to weight management, building on the extraordinary success of single-target GLP-1 agonists (semaglutide/Wegovy) and dual-target GIP/GLP-1 agonists (tirzepatide/Mounjaro). The next frontier is combining GLP-1 with amylin receptor agonism — an approach exemplified by Novo Nordisk's CagriSema (cagrilintide + semaglutide).
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta-cells. Like GLP-1, it delays gastric emptying and promotes satiety, but through a distinct receptor system (the amylin receptor, composed of calcitonin receptor + RAMP proteins). By targeting both the GLP-1 and amylin pathways simultaneously, researchers hypothesise that greater weight loss can be achieved than with either pathway alone.
This page examines the scientific rationale, clinical trial data, and future direction of multi-receptor weight loss approaches — all within the UK regulatory context.
**Critical Disclaimer:** CagriSema and other multi-receptor combinations discussed here are investigational compounds NOT approved for use. They are only available within clinical trials. This content is educational only and does not constitute medical advice or a recommendation.
Synergistic Mechanism
Multi-Receptor Synergy
Why Multiple Receptors?
Single-target GLP-1 agonists achieve approximately 15-17% weight loss (semaglutide 2.4mg). While clinically meaningful, this leaves significant room for improvement — the majority of treated patients do not reach a normal BMI. The body's weight regulatory system involves multiple redundant pathways, and targeting only one allows compensatory responses through others.
The GLP-1 + Amylin Rationale
GLP-1 pathway (semaglutide component):
- Hypothalamic appetite suppression
- Delayed gastric emptying
- Glucagon suppression
- Beta-cell support
Amylin pathway (cagrilintide component):
- Area postrema satiety signalling (distinct from GLP-1 brainstem targets)
- Complementary gastric emptying delay
- Glucagon suppression via different mechanism
- Potential effects on food reward pathways
The key insight is that these pathways are **complementary, not redundant**. GLP-1 acts primarily through the nucleus tractus solitarius and hypothalamic arcuate nucleus, while amylin signals predominantly through the area postrema. By activating both simultaneously, a more comprehensive suppression of appetite and energy intake may be achieved.
The Triple Agonist Frontier
Beyond dual-receptor approaches, triple agonists are in development:
- **Retatrutide (GLP-1/GIP/glucagon):** Phase 2 data showed ~24% weight loss — the glucagon component adds thermogenic effects and hepatic fat reduction
- **Survodutide (GLP-1/glucagon):** Phase 2 data showed significant weight loss and MASH resolution
- These represent further exploration of the multi-receptor hypothesis
Research Evidence
Clinical Trial Evidence
CagriSema (Cagrilintide + Semaglutide)
CagriSema is the most advanced combined GLP-1/amylin formulation:
Phase 2 Trial Results:
- 68-week study in adults with obesity (BMI ≥30 or ≥27 with comorbidities)
- CagriSema achieved approximately **15.6% weight loss** at the tested doses
- Semaglutide alone: ~15.8% (comparable)
- Cagrilintide alone: ~8.1%
- The Phase 2 results did not show dramatic superiority over semaglutide alone
Phase 3 Programme (REDEFINE):
- Multiple large-scale trials ongoing
- Testing optimised dose combinations that may show greater differentiation
- Results expected from 2025 onwards
- Novo Nordisk anticipates CagriSema could achieve >20% weight loss at optimised doses
Retatrutide (Triple Agonist)
Phase 2 Trial Results (Published in NEJM):
- 48-week study
- Highest dose group achieved **24.2% weight loss** — the largest ever reported in a Phase 2 obesity trial
- Additional benefits observed: reduction in liver fat (>80% reduction in MASLD patients)
- Phase 3 trials underway
Survodutide (GLP-1/Glucagon Dual Agonist)
Phase 2 Trial Results:
- 46-week study
- Achieved up to **18.7% weight loss**
- Significant MASH resolution and liver fibrosis improvement
- Glucagon component contributes thermogenic and hepatic benefits
Comparative Context
| Compound | Targets | Phase | Weight Loss | Key Advantage |
|----------|---------|-------|-------------|---------------|
| Semaglutide 2.4mg | GLP-1 | Approved | ~15-17% | Proven, available |
| Tirzepatide 15mg | GLP-1/GIP | Approved | ~20-26% | Superior efficacy |
| CagriSema | GLP-1/Amylin | Phase 3 | ~15-20%+ | Complementary pathways |
| Retatrutide | GLP-1/GIP/Glucagon | Phase 3 | ~24% | Triple mechanism |
| Survodutide | GLP-1/Glucagon | Phase 3 | ~19% | Liver benefits |
We do not publish stack protocols
Peptide Authority does not publish doses, reconstitution recipes, injection schedules, or cycle lengths for combinations of unlicensed peptides. This is a deliberate editorial position — we are an evidence and risk-intelligence publisher, not a prescriber. The reasoning is set out in detail in our no dosing, no sourcing policy.
For an honest review of what proponents of this kind of combination claim versus what the published evidence actually supports, see the combination claim-reviews. If you are considering any peptide medicine, speak to a GMC-registered doctor or GPhC-registered pharmacist.
Expected Outcomes
Expected Outcomes — Current and Future
Currently Available (Tirzepatide)
Based on SURMOUNT trial data:
- **Weight loss:** 15-26% of body weight at maximum dose (dose-dependent)
- **HbA1c reduction:** 2.0-2.5% in patients with T2D
- **Waist circumference:** ~15-20cm reduction
- **Blood pressure:** Modest reduction (~5-7 mmHg systolic)
- **Lipid profile:** Improvements in triglycerides and cholesterol
Expected from CagriSema (When Available)
Based on Phase 2 data and optimised Phase 3 dosing:
- **Weight loss:** Potentially >20% (Phase 3 data pending)
- **Additional satiety:** Dual-pathway appetite suppression
- **Glycaemic benefits:** Both components improve glucose control
Expected from Retatrutide (When Available)
Based on Phase 2 data:
- **Weight loss:** Potentially >24% at optimal dose
- **Liver fat reduction:** Dramatic improvements (>80% reduction)
- **Metabolic benefits:** Comprehensive metabolic improvement from triple agonism
Important Caveats
- Phase 2 results may not replicate in larger Phase 3 trials
- Long-term safety data (>2 years) is limited for all newer compounds
- Individual responses vary significantly — not all patients achieve average results
- Weight regain occurs in most patients upon discontinuation
Safety Considerations
Safety Considerations
GLP-1 Agonist Class Effects (Well-Characterised)
- **Gastrointestinal:** Nausea, vomiting, diarrhoea, constipation (most common, typically improves over time)
- **Pancreatitis:** Rare but serious
- **Gallbladder disease:** Increased risk during rapid weight loss
- **Thyroid:** C-cell tumour signal in rodents (relevance to humans uncertain)
- **Injection site reactions:** Mild, transient
Amylin Analogue-Specific Concerns
- **Nausea:** Amylin analogues also cause GI side effects — combination may increase GI burden
- **Pramlintide experience:** The only approved amylin analogue (for diabetes) caused significant nausea at initiation
- **Hypoglycaemia:** When combined with insulin (relevant for diabetic patients)
Multi-Receptor Combination Concerns
- **Additive GI effects:** Combining multiple pathways that each slow gastric emptying may increase nausea and vomiting
- **Unknown interactions:** Novel combinations may produce unexpected adverse effects
- **Long-term safety:** No compounds in the multi-receptor space have >5 years of safety data
Monitoring Recommendations (For Approved Treatments)
- Regular weight and BMI monitoring
- HbA1c and fasting glucose (particularly if pre-diabetic)
- Liver function tests
- Lipid panel
- Blood pressure
- Report persistent severe abdominal pain (pancreatitis screening)
Frequently Asked Questions
Conclusion
The pursuit of multi-receptor weight loss therapies represents the next chapter in metabolic medicine. Building on the transformative success of GLP-1 agonists and dual GLP-1/GIP agonists, the pharmaceutical pipeline includes combinations targeting amylin, glucagon, and potentially other pathways.
For UK patients seeking the most effective currently available treatment, tirzepatide (Mounjaro) already represents a multi-receptor approach with superior efficacy to single-target semaglutide. CagriSema, retatrutide, and survodutide offer exciting future possibilities but remain investigational.
The most important message is that effective multi-receptor treatments are already available and accessible in the UK through NHS and private prescribing pathways. Patients should work with their healthcare providers to access these proven options rather than seeking unapproved compounds.
This content is for educational and informational purposes only. All investigational compounds discussed are available only within clinical trials. Approved weight management medications require a prescription. Consult qualified healthcare professionals for personalised medical advice.